The diabetic retinopathy market is likely to grow with an estimated CAGR of 5.8% from 2023 to 2033. The market share is estimated to worth US$ 8.82 billion in 2023.
Due to the increasingly high demand for diabetic retinopathy for damaged eye-retina patients on which, the diabetic retinopathy manufacturers are anticipated to generate high revenue of US$ 15.50 billion by 2033.
Demand for diabetic retinopathy is increasing with the complication related eye which is likely to treat with various eye injections and laser treatment for the disease are anticipated to increase the diabetic retinopathy market share in the forecast period from 2023 to 2033.
The patients keep in the medical conditions and are likely to examine by the doctors and experts, which leads to an increase in the diabetic retinopathy market size in the forecast period.
Cure the diabetic retinopathy disease that occurs due to unclear vision, blurriness, loss of central vision, and eye floaters, which are likely to increase the sales of diabetic retinopathy treatment.
Due to the symptoms such as blockage in the retina veins on which supply of blood unable to reach the retina which causes this disease which anticipated to increase in the adoption of diabetic retinopathy.
The doctors monitor the diseases to check the conditions of the patient's eye & likely to adopt the laser treatment or medical treatment, whichever is necessary. Due to this factor, the market growth is anticipated to boost the economy all around the globe.
Hence, the adoption of diabetic retinopathy is generating high revenue and is likely to overcome the rental disease by using an advanced technique by the doctors and medical field.
This disease is caused by several factors such as high blood pressure, excess use of tobacco during pregnancy, diabetes patients, anemia, and others, which are rising the demand for diabetic retinopathy treatment.
To overcome the disease, treatment, as well as self-care, is essential as per the doctor's advice which helps to fight the diabetic retinopathy. The manufacturing companies are likely to rising the production such as medicine, devices, and other necessary kits, which is increasing the market share.
Several medical experts are testing, monitoring, and working to cure the critical condition of diabetic retinopathy in better ways. This leads to rising in the diabetic retinopathy statistic in the coming year.
It is likely to progress in the medical field and grow the diabetic retinopathy market's key trends and opportunities during the forecast period from 2023 to 2033.
| Attribute | Details |
|---|---|
| Historical Value (2022) | US$ 8.43 billion |
| Current Year Value (2023) | US$ 8.82 billion |
| Expected Forecast Value (2033) | US$ 15.50 billion |
| Historical CAGR (2018 to 2022) | 3.7% |
| Projected CAGR (2023 to 2033) | 5.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The manufacturing industries and other research institutes are likely to increase the production of diabetic retinopathy devices and medicine to increase the growth of the market share in the coming years.
These are the key industries making a focal point on the adoption of diabetic retinopathy to generate huge revenue by making a better quality of diabetic retinopathy devices in the market.
The end-user companies are Hospitals, Clinics, Multi-specialist hospitals, healthcare centers, and others are anticipated to boost the market future growth.
The diabetic retinopathy market is going to boost the lion’s share in the coming forecast period from 2023 to 2033 as end-users are anticipated to increase in demand for diabetic retinopathy.
| Segment | 2022 Value Share in Global Market |
|---|---|
| Non-proliferative | 73.4% |
| Anti VEGF | 67.3% |
By type segment, the market is likely to categorize into proliferative and non-proliferative. The non-proliferative segment is likely to dominate the market size in the forecast period from 2023 to 2033. The non-proliferative segment dominated the market since non-proliferative diabetic retinopathy is the early stage of the disease and is more prevalent than the advanced stage, proliferative diabetic retinopathy. Non-proliferative diabetic retinopathy is often detected earlier during regular eye examinations, making it easier to diagnose and manage. Treatment options for non-proliferative diabetic retinopathy are less invasive and less costly, involving lifestyle changes, blood sugar control, and regular eye monitoring. Healthcare providers focus on prevention and early detection to manage non-proliferative diabetic retinopathy effectively and prevent its progression to proliferative diabetic retinopathy. Clinical research and trials have also been more focused on developing treatments for non-proliferative diabetic retinopathy. Furthermore, managing non-proliferative diabetic retinopathy is generally more cost-effective than managing proliferative diabetic retinopathy, leading healthcare systems to prioritize the treatment of the more common non-proliferative diabetic retinopathy cases.
Based on management, anti-VEGF is anticipated to dominate the diabetic retinopathy market growth as compared to other segments, including laser surgery, Intraocular steroid injection, and vitrectomy. The adoption of diabetic retinopathy is likely to grow the height of the market through the anti-VEGF segment in the forecast period from 2023 to 2033. The dominance of the anti-VEGF segment in the treatment of diabetic retinopathy can be attributed to its high efficacy, supported by strong clinical evidence and a favorable safety profile. Anti-VEGF drugs have shown remarkable effectiveness in managing diabetic retinopathy, particularly in cases involving abnormal blood vessel growth in the retina, leading to vision loss. These drugs work by targeting the Vascular Endothelial Growth Factor, which helps reduce the growth of abnormal blood vessels and associated complications. As a result of their proven success, healthcare professionals and patients have embraced anti-VEGF drugs as a preferred treatment option over alternatives like laser photocoagulation and corticosteroids. Moreover, ongoing research and development efforts by pharmaceutical companies are likely to improve the effectiveness of these drugs further, solidifying their position in the market.
Principal Consultant
| Region | 2022 Value Share in Global Market |
|---|---|
| North America | 41% |
| Europe | 23.4% |
The diabetic retinopathy market size is likely to increase all around the region, which is segmented by North America, Asia Pacific, Europe, Latin America, and other regions. The North American region is dominating all the remaining regions during the forecast period from 2023 to 2033.
| Country | 2022 Value Share in Global Market |
|---|---|
| United States | 32.1% |
| Germany | 4.6% |
| Japan | 3.5% |
| Country | Value CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 5.4% |
| China | 5.6% |
| India | 6.4% |
The US country is estimated to dominate the market all around the globe due to the widespread production and distribution of diabetic retinopathy devices and products worldwide. The government of the USA initiative plans and policies for the growth of the market, and due to well-established infrastructure, the demand for diabetic retinopathy is supposed to increase all around the regions.
The United States has witnessed a significant rise in the prevalence of diabetes, primarily due to factors such as sedentary lifestyles, unhealthy diets, and an aging population. The prevalence of diabetic retinopathy in the United States is a significant concern, with it being the primary cause of new cases of blindness among adults aged 20 to 74 years. According to data released by the Centers for Disease Control and Prevention (CDC) in 2020, about 4.1 million Americans suffer from diabetic retinopathy, and close to 900,000 individuals face the risk of vision impairment due to this condition. As the number of people living with diabetic retinopathy continues to rise, it is anticipated to drive market growth across the country.
The United States has witnessed a growing integration of AI in ophthalmic diagnostics and screening processes. AI-powered systems can analyze retinal images and detect diabetic retinopathy with high accuracy, leading to early intervention and personalized treatment plans. The United States has stringent regulations concerning the approval and marketing of ophthalmic drugs and medical devices. Companies operating in this market must adhere to the guidelines set by the Food and Drug Administration (FDA) to ensure product safety and efficacy.
In Germany, out of the adult population, 8.8% reported having been diagnosed with diabetes, with 9.3% of women and 8.2% of men indicating they had received such a diagnosis. This has resulted in an increased demand for diabetic retinopathy management and treatment options, driving the market growth. Germany has a robust healthcare system, encouraging investments in research and development. The country has witnessed significant advancements in diagnostic tools and treatment options for diabetic retinopathy, such as retinal imaging technologies, laser therapies, and intravitreal injections. There is a growing trend towards personalized medicine in Germany. Tailored treatments, including individualized treatment plans for diabetic retinopathy patients, are becoming more prevalent, leading to better patient outcomes.
China stood in the second position in the adoption of diabetic retinopathy in the Asia-Pacific region, with a CAGR of 5.6% in the forecast period from 2023 to 2033.
The rising awareness, increasing population, and rise in disposable income are likely to boost the market size in the forecast period in the Asia-Pacific region.
With the increasing prevalence of diabetes in China, the incidence of diabetic retinopathy has also risen significantly. In China, the prevalence of diabetes among individuals aged 20 to 79 years surged from 4.7% in 1990 to 8.0% in 2019, indicating a substantial 71.1% increase. The primary driver behind this increase is predominantly attributed to unhealthy lifestyles, characterized by diets high in sugar and fat, coupled with insufficient physical activity. Remarkably, China holds the distinction of having the highest diabetic population globally, with about 141 million people affected by the disease. Projections suggest that by the year 2045, this number is expected to escalate to around 174 million individuals living with diabetes in the country. China has an aging population, with a significant proportion of individuals aged 65 and above. The elderly population is more susceptible to both diabetes and diabetic retinopathy, creating a substantial demand for specialized care and treatments.
The United Kingdom is estimating a higher growth in the diabetic retinopathy market and is likely to surge the high revenue with a CAGR of 45.4% in the forecast period.
The United Kingdom has experienced a rise in diabetes cases, mainly attributed to sedentary lifestyles, unhealthy dietary habits, and an aging population. As of 2023, around 7% of the population is currently living with diabetes, comprising about one million individuals with undiagnosed type 2 diabetes. Additionally, there are about 40,000 children with diabetes, and over 3,000 children receive new diagnoses each year. This trend has subsequently led to a higher prevalence of diabetic retinopathy, driving the demand for effective diagnostic and treatment options. The NHS plays a crucial role in the United Kingdom healthcare landscape. The Diabetic Eye Screening Program provided by the NHS offers diabetic retinopathy screenings to individuals with diabetes. This program has significantly contributed to the early detection and management of diabetic retinopathy cases.
Other countries such as Japan and South Korea are supposed to grow the diabetic retinopathy market in the coming year. All these regions are looking forward to growing the market higher & contributing to the healthcare sector.
The diabetic retinopathy market in Japan is experiencing steady growth owing to an increasing prevalence of diabetes in the country. Diabetes mellitus (DM) poses a significant public health challenge in Japan, with about 12% of the population reported to have diabetes in 2016, as per a national survey. In the broader western Pacific region, the estimated prevalence of diabetes was 162.6 million (9.6%) in 2019, and Japan's diabetes cases reached 7.39 million patients (5.6%) in the same year. The increase in diabetes prevalence in Japan is primarily attributed to the adoption of a Westernized lifestyle and the effects of an aging population. Japan has one of the world's top proportions of elderly individuals, and this demographic is more susceptible to diabetes and diabetic retinopathy.
India has witnessed a significant increase in the prevalence of diabetes over the past decade. According to the International Diabetes Federation (IDF) data from 2020, there were 463 million people globally who had diabetes, with 88 million of those cases found in the Southeast Asia region. Within this region, India accounted for a significant portion, with 77 million individuals diagnosed with diabetes. Additionally, there were about 25 million people in India classified as pre-diabetics, putting them at a higher risk of developing diabetes in the near future. The prevalence of diabetes in the population was reported to be 8.9% based on IDF statistics. The rising diabetic population directly correlates with the prevalence of diabetic retinopathy cases.
India is currently experiencing various environmental and lifestyle changes due to factors such as industrialization, migration to urban areas, rising per capita spending, and a growing culture of eating out. As a consequence, there has been an increase in the consumption of food items that are high in calories, fat, and sugar content. These changes in dietary habits and lifestyle patterns have contributed to the escalating diabetes burden in the country. As India grapples with a rising diabetes epidemic, the demand for diabetic retinopathy treatments and management is expected to surge.
The end use industries and manufacturing companies play a key role in surging the diabetic retinopathy market size. The sales of diabetic retinopathy are likely to rise in these industries by capturing the tactics including mergers, collaboration, and partnerships.
Some of the key companies are present to highlight the lion’s share in the diabetic retinopathy market. These are Bayer Healthcare, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc, Oxurion, and others.
These industries prefer better quality treatment devices and medical uses in the market trends and opportunities in the coming year.
Recent Developments
CheckEye, a company located in Kyiv, came up with a groundbreaking approach to address diabetic retinopathy in January 2023. Their cutting-edge cloud-based solution can swiftly detect diabetic retinopathy along with seven other eye conditions, all within a ten-minute test. This test enables early identification of potential issues in diabetic patients' vision, and it can also serve as an alert to physicians for possible diabetes cases.
Eyenuk, a well-known worldwide digital health firm that specializes in artificial intelligence (AI) and is the leading supplier of AI Eye Screening and AI Predictive Biomarkers solutions, received regulatory clearance to launch its EyeArt AI eye screening system in the European Union in January 2023. This certification includes new uses such as detecting age-related macular degeneration (AMD) and glaucomatous optic nerve damage, which is symptomatic of glaucoma.
Regeneron Pharmaceuticals, Inc. announced in June 2022 that the United States Food and Drug Administration (FDA) had approved the supplementary Biologics License Application (sBLA) for EYLEA (aflibercept) Injection. Following the initial monthly dosages, the sBLA is evaluated for the 2 mg dosing schedule every 16 weeks, primarily for individuals with diabetic retinopathy (DR).
REGENXBIO Inc. released more promising interim data from the current Phase II ALTITUDE study of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) via in-office suprachoroidal administration in February 2022.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The projected revenue of the market by 2033 is US$ 8.82 billion.
The market CAGR for 2033 is projected to be 5.8%.
The market is valued at US$ 15.50 billion in 2023.
North America holds the largest market share.
The challenge for the Diabetic Retinopathy Market is the cost, awareness gaps, healthcare limits, and treatment side effects hinder diabetic retinopathy care worldwide.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Proliferative
5.3.2. Non-proliferative
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Management
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Management, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Management, 2023 to 2033
6.3.1. Anti VEGF
6.3.2. Intraocular Steroid Injection
6.3.3. Laser Surgery
6.3.4. Vitrectomy
6.4. Y-o-Y Growth Trend Analysis By Management, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Management, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By Management
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By Management
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type
9.2.3. By Management
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Management
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Type
10.2.3. By Management
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Management
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Type
11.2.3. By Management
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Management
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Type
12.2.3. By Management
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Management
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Type
13.2.3. By Management
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Management
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Type
14.2.3. By Management
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Management
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Type
15.1.2.2. By Management
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Type
15.2.2.2. By Management
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Type
15.3.2.2. By Management
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Type
15.4.2.2. By Management
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Type
15.5.2.2. By Management
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Type
15.6.2.2. By Management
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Type
15.7.2.2. By Management
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Type
15.8.2.2. By Management
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Type
15.9.2.2. By Management
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Type
15.10.2.2. By Management
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Type
15.11.2.2. By Management
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Type
15.12.2.2. By Management
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Type
15.13.2.2. By Management
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Type
15.14.2.2. By Management
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Type
15.15.2.2. By Management
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Type
15.16.2.2. By Management
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Type
15.17.2.2. By Management
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Type
15.18.2.2. By Management
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Type
15.19.2.2. By Management
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Type
15.20.2.2. By Management
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Type
15.21.2.2. By Management
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Type
15.22.2.2. By Management
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Type
15.23.2.2. By Management
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type
16.3.3. By Management
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Bayer Healthcare
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Novartis AG
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Regeneron Pharmaceuticals Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Allergan plc
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Oxurion
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Sirnaomics, Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Genentech
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Glycadia Pharmaceuticals
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Alimera Sciences
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Ampio Pharmaceuticals
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. BCN Peptides
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Kowa Group
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Diabetic Retinopathy Market
